©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
The Different Activities of the Two Activation Domains of the Brn-3a Transcription Factor Are Dependent on the Context of the Binding Site (*)

(Received for publication, October 24, 1995; and in revised form, December 21, 1995)

Vishwanie Budhram-Mahadeo Peter J. Morris Nick D. Lakin (§) Sally J. Dawson David S. Latchman (¶)

From the Medical Molecular Biology Unit, Department of Molecular Pathology, University College London Medical School, The Windeyer Building, Cleveland Street, London W1P 6DB, United Kingdom

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The POU (Pit-Oct-Unc) family transcription factor Brn-3a contains two distinct activation domains, one at the N terminus of the molecule and one at the C terminus coincident with the DNA binding domain. These different activation domains have been shown previously to differ in their ability to activate an artificial test promoter containing a Brn-3a binding site and the naturally occurring alpha-internexin gene promoter. Here we identify the target site for Brn-3a in the alpha-internexin gene promoter and show that it can confer responsiveness to Brn-3a on a heterologous promoter. One of the single-stranded DNA sequences derived from either this novel Brn-3a binding site or from the previously characterized site in the test promoter are shown to bind Brn-3a preferentially compared with the complementary single strand or the corresponding double-stranded sequence. The pattern of responsiveness of these two sequences when cloned upstream of the same test promoter and co-transfected with constructs encoding various portions of Brn-3a indicates that the activity of the two Brn-3a activation domains is dependent upon differences in the context of the target sequence in each promoter rather than on differences in the target sequence itself.


INTRODUCTION

The POU (Pit-Oct-Unc) family of transcription factors play a critical role in the regulation of gene expression in neuronal cells acting by binding to sequences related to the consensus octamer motif ATGCAAAT in the promoters of their target genes (for review, see Verrijzer and van der Vliet(1993) and Wegner et al. (1993)). The Brn-3 family of mammalian POU factors are of particular interest as the mammalian factors most closely related to the nematode POU protein Unc-86 whose inactivation results in the failure to develop specific neuronal cell types particularly sensory neurons (Desai et al., 1988; Finney et al., 1988). Three mammalian Brn-3 factors encoded by distinct genes exist (Theil et al., 1993, 1994) and are known as Brn-3a (also known as Brn-3.0: Gerrero et al., 1993; Lillycrop et al., 1992), Brn-3b (also known as Brn-3.2: Lillycrop et al., 1992; Turner et al., 1994), and Brn-3c (also known as Brn-3.1: Gerrero et al., 1993; Ninkina et al., 1993).

In agreement with their similarity to Unc-86, all three of these factors are expressed in sensory neurons and exhibit distinct but related patterns of gene expression in the developing and adult nervous systems (Gerrero et al., 1993; He et al., 1989; Lillycrop et al., 1992; Ninkina et al., 1993; Theil et al. 1993; Turner et al., 1994; Xiang et al., 1993). In addition they exhibit distinct and often opposite changes in gene expression in cultured neuronal cells exposed to growth factors or stimuli inducing differentiation (Budhram-Mahadeo et al., 1995a, 1995b; Lillycrop et al., 1992).

These differences in expression pattern are paralleled at the functional level. Thus Brn-3a can activate artificial test promoters bearing octamer-related motifs (Budhram-Mahadeo et al., 1994; Morris et al., 1994) or a binding site derived from the pro-opiomelanocortin promoter (Gerrero et al., 1993) and can also activate the naturally occurring promoters of the pro-opiomelanocortin (Turner et al., 1994) or alpha-internexin (Budhram-Mahadeo et al., 1995b) genes. In contrast Brn-3b has been shown to repress both the test promoter bearing the octamer-related motif (Budhram-Mahadeo et al., 1994) and the alpha-internexin promoter (Budhram-Mahadeo et al., 1995b) and can interfere with their activation by Brn-3a (BudhramMahadeo et al., 1994, 1995b; Morris et al., 1994).

In view of the activation of these two promoters by Brn-3a and not Brn-3b, we have used chimeric constructs encoding different regions of Brn-3a or Brn-3b to map the regions of Brn-3a required for promoter activation. In these experiments, activation of the octamer-containing test promoter is dependent on the DNA-binding POU domain of Brn-3a (Morris et al., 1994). In contrast, activation of the alpha-internexin promoter requires a domain at the N terminus of Brn-3a (BudhramMahadeo et al., 1995b). In agreement with this difference observed using chimeric constructs, the isolated POU-domain of Brn-3a when expressed in the absence of other regions can activate the octamer-containing test promoter but not the alpha-internexin promoter (Budhram-Mahadeo et al., 1995b).

Hence Brn-3a contains two distinct activation domains which differ in their ability to activate different target promoters. Interestingly, although the alpha-internexin promoter contains several copies of the octamer motif (Ching and Liem, 1991), these are not required for activation by Brn-3a. Thus Brn-3a can activate a truncated alpha-internexin promoter containing only 77 bases of upstream sequence and lacking any sequences closely related to the octamer motif (Budhram-Mahadeo et al., 1995b). The difference in the effects of different activation domains of Brn-3a on the two test promoters may thus arise from a difference in sequence between the octamer motif and the target sequence in the alpha-internexin promoter. Alternatively it may be dependent on differences in the context of the Brn-3a target site relative to other transcription factor binding sites in the two promoters.

To distinguish these possibilities we have identified the target site for Brn-3a in the alpha-internexin promoter and have tested the effect of different Brn-3a constructs upon this sequence when it is placed in the same context as the octamer motif within a test promoter.


MATERIALS AND METHODS

Plasmid DNAs

The initial alpha-internexin promoter construct containing sequences from -77 to +73 relative to the transcriptional start site has been described previously (Budhram-Mahadeo et al., 1995b; Ching and Liem, 1991). Other constructs were derived by linerization at the BglII site at -77 and partial digestion with Bal-31 exonuclease. The end points of the digest within the promoter sequence was determined by DNA sequence analysis. A double-stranded oligonucleotide containing the alpha-internexin promoter sequence from -77 to -61 with a single-stranded 5`-GATC-3` sequence at either end was synthesized. This oligonucleotide and the corresponding single-stranded oligonucleotides labeled to equal specific activities with P were used in DNA mobility shift assays with in vitro transcribed and translated Brn-3a and b proteins as described previously (Morris et al., 1994).

For the binding assay, 10 fmol of [P]ATP-labeled oligonucleotide probe was mixed with reticulocyte lysate in the presence of 20 mM Hepes, 5 mM MgCl(2), 50 mM KCl, 0.5 mM dithiothreitol, 4% Ficoll, and 2 µg of poly(dI-dC)/20-µl reaction volume. Competitor DNA was added at appropriate molar excess at this stage, as required. The binding reaction was incubated on ice for 40 min prior to electrophoresis on a 4% polyacrylamide gel in 0.25 times TBE (1 times TBE = 100 mM Tris/HCl, 100 mm-boric acid, 2 mM EDTA, pH 8.3) for 2-3 h at 150 V and 4 °C. DNA-protein complexes were visualized by autoradiography of the dried gel.

The double-stranded oligonucleotide was cloned into the BamHI site in the vector pBLCAT2 that contains the herpes simplex virus thymidine kinase promoter driving the cat gene (Luckow and Schutz, 1987). The response of this plasmid reporter was compared with that used in our previous experiments (Budhram-Mahadeo et al., 1994, 1995b), which contains the Brn-3 octamer-related binding site ATGCAATT cloned into the same site in the vector pBLCAT2. The Brn-3a and -3b expression vectors contain full-length cDNA or genomic clones for each of these proteins (Theil et al., 1993) cloned under the control of the Moloney murine leukemia virus promoter in the vector pLTR poly which has been modified by deletion of a cryptic splice site in the SV40 3`-untranslated region.

DNA Transfection

Transfection of DNA was carried out according to the method of Gorman (Gorman, 1985). Routinely 1 times 10^6 BHK-21 cells (Macpherson and Stoker, 1962) or ND7 cells (Wood et al., 1990) were transfected with 10 µg of the reporter plasmid and 10 µg of the Brn-3 expression vectors. In all cases cells were harvested 72 h later. The amount of DNA taken up by the cells in each case was measured by slot blotting the extract and hybridization with a probe derived from the ampicillin resistance gene in the plasmid vector. This value was then used to normalize the values obtained in the chloramphenicol acetyltransferase assay as a control for differences in uptake of plasmid DNA in each sample.

Chloramphenicol Acetyltransferase Assay

Assays of chloramphenicol acetyltransferase activity were carried out according to the method of Gorman (Gorman, 1985) using samples that had been equalized for protein content as described by the method of Bradford (Bradford, 1976).


RESULTS

In our previous experiments, a construct containing alpha-internexin promoter sequences from -77 to +73 relative to the transcriptional start site was strongly inducible by Brn-3a (Budhram-Mahadeo et al., 1995b). To further delineate the sequences in the promoter mediating this inducibility, this plasmid was digested with the Bal-31 exonuclease to produce a construct which on sequence analysis contained alpha-internexin promoter sequences from -46 to +73. As indicated in Fig. 1, inducibility by Brn-3a was completely abolished in the -46 construct, although this construct retained detectable basal promoter activity, indicating that the lack of inducibility was not due to the absence of a functional promoter.


Figure 1: Activation of alpha-internexin promoter constructs containing sequences from -77 or -46 to +73 relative to the transcriptional start site, upon co-transfection with the Brn-3a transcription factor. In each case results are expressed as -fold activation of promoter activity upon co-transfection of 5 µg of target plasmid with 10 µg of a Brn-3a expression vector compared with the activity observed with the expression vector lacking insert alone.



These findings indicate that alpha-internexin promoter sequences located between -77 to -47 upstream of the transcriptional start site are required for inducibility by Brn-3a. Inspection of this sequence revealed a sequence at -68 to -61 that shared a five out of eight base pair match to the octamer-related motif we used in our previous studies (BudhramMahadeo et al., 1994; Morris et al., 1994) and to the consensus octamer motif (Fig. 2). Moreover this motif retained the ATG sequence previously shown to be of critical importance for Brn-3a to bind to its response element in the pro-opiomelanocortin promoter (Gerrero et al., 1993) and in various synthetic oligonucleotides (Li et al., 1994). We therefore tested the binding of Brn-3a to an oligonucleotide consisting of the alpha-internexin promoter sequence from -77 to -60 that contained this motif.


Figure 2: Sequence of the consensus octamer motif (A: Falkner et al., 1996), compared with the octamer-related motif used in our previous studies (B: Ching and Liem, 1991) or the sequence from -68 to -61 in the alpha-internexin promoter (C: Morris et al., 1994).



As illustrated in Fig. 3, this double-stranded oligonucleotide was able to bind in vitro transcribed and translated Brn-3a, but did so rather poorly in DNA mobility shift assays. Surprisingly, however, as shown in Fig. 3, strong binding of Brn-3a was observed with one of the two corresponding single-stranded oligonucleotides containing the antisense strand of the alpha-internexin gene sequence (complementary to the sequence illustrated in Fig. 2). Some binding of Brn-3a was also observed with the other single-stranded oligonucleotide containing the sense strand of the alpha-internexin gene. This binding was not observed with control reticulocyte lysates that had not been stimulated with mRNA or that expressed other unrelated in vitro transcription/translation products (data not shown).


Figure 3: DNA mobility shift assay using in vitro transcribed and translated Brn-3a protein and P-labeled probes derived from the single-stranded antisense sequence of the alpha-internexin promoter from -77 to -60 (A), the complementary sense sequence (S), or the corresponding double-stranded oligonucleotide (D). The positions of the single- and double-stranded oligonucleotides are indicated by the horizontal lines.



This result, therefore, confirms that the region of the alpha-internexin promoter from -77 to -60 can indeed bind Brn-3a paralleling the role of this region in the Brn-3a responsiveness of the promoter. However, the binding occurs with much higher affinity to one of the two corresponding single-stranded sequences compared with the double-stranded sequence.

As binding of Brn-3a to single- rather than double-stranded sequences had not been reported previously, we wished to test whether it was a peculiarity of the alpha-internexin sequence or could also be observed with other target sites for Brn-3a. We therefore tested the binding of Brn-3a to the octamer-related sequences used in our previous studies (Morris et al., 1994) (oligonucleotide B in Fig. 2). In accordance with our previous data, Brn-3a bound to this double-stranded oligonucleotide (Fig. 4A). However, as with the alpha-internexin sequence, much stronger sequence-specific binding was observed to the antisense oligonucleotide (complementary to the sequence illustrated in Fig. 2) with somewhat weaker binding being observed with the other single-stranded oligonucleotide (Fig. 4A), and this was confirmed by competition analysis (Fig. 4B). Most importantly, in these experiments, no competition for binding to the single-stranded sequence was observed with unrelated competitor oligonucleotides confirming that the binding was sequence specific (Fig. 4B). This sequence specificity was observed for both complexes formed by Brn-3a that may represent the binding of monomeric and dimeric Brn-3a.


Figure 4: A, DNA mobility shift assay using in vitro transcribed and translated Brn-3a protein and P labeled probes derived from the double stranded octamer-related sequence (track 1), the single-stranded sense sequence (track 2), or the complementary antisense sequence (track 3). B, DNA mobility shift assay using in vitro transcribed and translated Brn-3a protein and P labeled probe derived from the single-stranded antisense octamer either alone (track 1), or in the presence of one hundredfold excess of unlabeled homologous oligonucleotide (track 2), unlabeled sense strand (track 3), unlabeled double strand (track 4), unlabeled antisense sequence from the alpha-internexin promoter (track 5), or an unrelated oligonucleotide (track 6).



In these experiments the binding affinity of the octamer-related sequence for Brn-3a appeared to be higher than that of the alpha-internexin sequence when the amount of either antisense single-stranded or double-stranded probe bound in each case was compared. In agreement with this, unlabeled alpha-internexin antisense sequence competed relatively poorly for Brn-3a bound to labeled antisense octamer-related sequence compared to the degree of competition observed with unlabeled homologous competitor (Fig. 4B, track 4).

In similar experiments, Brn-3b also exhibited preferential binding to the antisense strand of each sequence compared with its binding to the corresponding sense strand or double-stranded sequence, indicating that this preference is common to Brn-3a and Brn-3b (Fig. 5). Thus these observations indicate that Brn-3a and Brn-3b can bind to at least two specific sequences with higher affinity for one of the two single-stranded sequences than for the corresponding double-stranded sequence.


Figure 5: DNA mobility shift assay with in vitro transcribed and translated Brn-3b protein and P labeled probes derived from the antisense sequence of the alpha-internexin promoter (A), the complementary sense strand sequence (S), or corresponding double-stranded oligonucleotide.



In our previous experiments (Budhram-Mahadeo et al., 1995b; Morris et al., 1994) both the synthetic octamer-related sequence upstream of the thymidine kinase promoter and the alpha-internexin promoter were activated by Brn-3a and not by Brn-3b. However these two promoters responded differently to constructs encoding chimeric proteins containing different regions derived from Brn-3a and Brn-3b (Fig. 6), indicating that the alpha-internexin promoter was activated by an activation domain located at the N terminus of Brn-3a, whereas activation of the synthetic octamer-related sequence was dependent on the POU domain of Brn-3a. Such a difference might be due to the difference in sequence between the two Brn-3a binding sites (Fig. 2) or to the different context of each sequence relative to other sequences in the two different promoters.


Figure 6: Summary of gene trans-activation data obtained using either the tK promoter carrying a synthetic octamer motif (tK-Oct) (data from Morris et al., 1994) or carrying the response element from the alpha-internexin promoter (tk-int) (Fig. 7) or with the intact alpha-internexin promoter (Budhram-Mahadeo et al., 1995b) together with Brn-3a or -b or with constructs encoding chimeric proteins with different regions derived from Brn-3a or Brn-3b. The division of Brn-3a and -3b subdomains I, II, III, and IV is as follows. For Brn-3a: domain I, amino acids 1-40; domain II, amino acids 41-108; domain III, amino acids 109-267; domain IV (POU domain), amino acids 268 to the end. For Brn-3b; subdomain II, amino acids 1-92; subdomain III, amino acids 93-169; subdomain IV (POU domain), amino acids 170-end.




Figure 7: Chloramphenicol acetyltransferase assay following transfection of a construct in which the sequence from -77 to -60 in the alpha-internexin promoter has been cloned upstream of the tK promoter in the plasmid pBLCAT2. 5 µg of this construct was co-transfected with 10 µg of either expression vector lacking any insert (V) or the same vector containing inserts encoding Brn-3a (A), Brn-3b (B) or the chimeric constructs (1-4) numbered as in Fig. 6. Values are expressed relative to that obtained upon co-transfection with expression vector alone and are the average of three independent experiments whose standard deviation is shown by the bars.



To distinguish between these possibilities, the double-stranded oligonucleotide containing the alpha-internexin sequence from -77 to -60 was cloned into the BamHI site in the vector pBLCAT2 (Luckow and Schutz, 1987), thereby placing it at -115 relative to the transcriptional start site of the thymidine kinase promoter the same position as the octamer-related sequence in the pBCLCat2-derived construct used in our previous experiments (Morris et al., 1994).

In these experiments (Fig. 7) the thymidine kinase promoter containing the alpha-internexin sequence was activated by Brn-3a, confirming that the binding of Brn-3a to the alpha-internexin sequence from -77 to -60 was able to produce transcriptional activation of a heterologous promoter. Moreover this promoter construct was not activated by Brn-3b, allowing us to use the chimeric constructs to determine the region of Brn-3a required for activation. Interestingly, the ability of these constructs to activate the thymidine kinase promoter containing the alpha-internexin sequence was dependent on the POU domain being derived from Brn-3a and did not depend on the N-terminal region. Thus, for example, the promoter was activated by construct 4, which has the POU domain derived from Brn-3a but lacks the N-terminal domain, whereas construct 3, which has the N-terminal domain of Brn-3a but the POU domain of Brn-3b, did not activate the promoter (Fig. 7).

Hence the response of the alpha-internexin sequence to the chimeric constructs is identical to that of the octamer-related sequence when the two are cloned into the same context in the thymidine kinase promoter, although this sequence responds differently when in its natural context in the alpha-internexin promoter. We showed previously (Budhram-Mahadeo et al., 1995b) that the octamer-related sequence could also be activated by a construct expressing the Brn-3a POU domain in isolation, indicating that the POU domain of Brn-3a was not only necessary but also sufficient for activation of this construct as well as for DNA binding. In contrast, the natural alpha-internexin promoter was, as expected, not activated by this construct (Budhram-Mahadeo et al., 1995b). As shown in Fig. 8, however, when placed upstream of the thymidine kinase promoter, the alpha-internexin sequence was able to confer a response to the POU domain of Brn-3a exactly as occurred with the octamer-related sequence in the same promoter context. Moreover, as with the octamer-related sequence, the alpha-internexin sequence was not activated by Brn-3b.


Figure 8: Chloromphenicol acetyltransferase assay following transfection of 5 µg of the construct containing the -77 to -60 alpha-internexin sequence in pBLCAT2 together with 10 µg of either expression vector lacking any insert (V) or the same vector containing inserts encoding the isolated POU domains of either Brn-3a (A) or Brn-3b (B).




DISCUSSION

In the work presented here, we have extended out previous studies of the alpha-internexin promoter (Budhram-Mahadeo et al., 1995b) to show that its responsiveness to the Brn-3a transcription factor is dependent on a region from -77 to -47 relative to the transcriptional start site. Moreover, a portion of this region from -77 to -60 can bind Brn-3a or Brn-3b and confer responsiveness to activation by Brn-3a upon a heterologous promoter. The best match to the octamer motif (ATGCAAAT), which binds many POU factors in this region, is the sequence ATGAAGCT, which shows only a five out of eight match. This therefore confirms and extends previous findings that Brn-3a and Brn-3b can regulate promoter activity by binding to sequences either closely (Lillycrop et al., 1995; Morris et al., 1994) or more distantly (Gerrero et al., 1993; Li et al., 1994; Turner et al., 1994) related to the octamer motif.

More interestingly, however, we have shown for the first time that both Brn-3a and Brn-3b bind strongly and in a sequence-specific manner to one single strand of both the alpha-internexin promoter sequence and a sequence more closely related to the octamer motif. Moreover, this binding is considerably stronger than that observed to either the corresponding double-stranded sequence or the complementary single strand. Such behavior has never, to our knowledge, previously been described for a POU family transcription factor. Similar preferential binding to one single strand compared with the corresponding double-stranded sequence or the complementary single strand has been reported for proteins binding to specific regulatory sites in a number of other cases. These include proteins binding to the sterol regulatory element in the hydroxymethylglutaryl-CoA reductase and synthase genes (Stark et al., 1991), an inhibitory element in the growth hormone gene promoter (Pan et al., 1990), a regulatory region of the adipsin gene promoter (Wilkison et al., 1990) and an inhibitory region in the androgen receptor gene promoter (Grossman and Tindall, 1995). Similar preferential binding to one single strand has also been reported for the transcription factor Myef-2 (Haas et al., 1995) and for the estrogen receptor either alone or in association with another factor (Mukherjee and Chambon, 1990).

Several of these factors thus appear to bind to sequences that have been shown to have an inhibitory effect on promoter activity (Grossman and Tindall, 1995; Pan et al., 1990; Wilkison et al., 1990) and binding of the Myef-2 factor to its recognition element in the myelin basic protein gene promoter has also been shown to inhibit promoter activity (Haas et al., 1995). Indeed it has been suggested that binding of such factors could promote or maintain the DNA in a single-stranded form incapable of binding other factors necessary for transcription (Grossmann and Tudall, 1995). Interestingly, Brn-3b can also inhibit promoter activity and interfere with activation by Brn-3a (Budhram-Mahadeo et al., 1994, 1995b; Morris et al., 1994). It is possible, therefore, that binding of Brn-3a and Brn-3b may both produce structural alterations in the DNA, although in the case of Brn-3a, such changes activate transcription, whereas Brn-3b has the opposite effect.

In this regard it is obviously of interest that in some cases the isolated DNA binding domain of Brn-3a can act as an activation domain and stimulate transcription (Morris et al., 1994). In contrast, at least in the case of the alpha-internexin promoter, other mechanisms must operate which require the activation domain at the N terminus (Budhram-Mahadeo et al., 1995b). In other situations, where the activation domain of a specific factor can activate some promoters but not others, this effect has been shown to depend on either the nature of the binding site in each promoter or its context relative to other binding sites. Thus, for example, the glucocorticoid receptor can activate gene expression by binding to a glucocorticoid response element, but represses rather than activates following binding to a distinct sequence known as the nGRE (Sakai et al., 1988). In contrast the YY1 factor activates the human papilloma virus 18 promoter when an adjacent switching sequence is also present but represses the promoter by binding to the same target sequence when the switching element is absent (Bauknecht et al., 1995). Similarly, the activity of the Drosophila dorsal protein is affected by the presence or absence of adjacent binding sites for the dorsal switch protein (Lehming et al., 1994), while the Ubx protein binds to some DNA binding sites only when a binding site for the extradenticle protein is present (Van Dijk and Murre, 1994).

In the case of Brn-3a, we show here that the different effects of the two activation domains which we described previously (Budhram-Mahadeo et al., 1994, 1995b) are dependent on differences in the context of the binding site rather than its sequence the first time this effect has been deonstrated for two activation domains in the same molecule. Such an effect might depend on the ability of the Brn-3a DNA binding POU domain to open its binding site to a single-stranded form in the presence of different flanking sequences. Alternatively it could depend upon its ability to produce alterations in the structure of the different sequences adjacent to its binding sites and/or on whether an activating effect was produced by disrupting such sequences. In situations where DNA binding by the POU domain did not produce activation, the N-terminal activation domain would be required and would presumably act in a conventional manner by interacting with other promoter-bound factors.

Alternatively both the POU and N-terminal activation domains may act by interacting with other promoter-bound factors with the two activation domains differing in the factors with which they could interact. Thus promoter-specific activation by the two activation domains would depend upon differences between promoters in the nature of the transcription factors binding to the specific sequences in each promoter or in the composition of the basal transcriptional complex that binds at the TATA box in each promoter. In agreement with this latter possibility the TATA-binding protein-associated factors (TAFs) (^1)have been shown recently to play a role in promoter selectivity with different complexes assembling at different promoters (Verrijzer et al., 1995). Moreover the two activation domains located within either the estrogen receptor or the glucocorticoid receptor have each been suggested to interact with different TAFs (Tasset et al., 1990) reflecting the general finding that different classes of activation domain can interact with different TAFs (Chen et al., 1994).

Although further studies will evidently be required to clarify the precise mechanism, it is clear that the context of the binding site regulates activation by the two activation domains of Brn-3a. Interestingly the Brn-3a primary transcript can be alternatively spliced to yield mRNAs encoding proteins with and without the N-terminal activation domain, but both containing the POU domain (Gerrero et al., 1993), and the outcome of this process can be regulated by exposure of neuronal cells to specific stimuli. (^2)Thus the existence of two activation domains in Brn-3a may allow complex patterns of gene regulation in response to specific stimuli with some promoters being activated by both forms of Brn-3a and others only when the full size form is made, with such differential activation being dependent on the context of the Brn-3a binding site in the target promoter.


FOOTNOTES

*
This work was supported by the Medical Research Council and Wellbeing. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Present address: Wellcome/CRC Institute, Tennis Court Rd., Cambridge CB2 1QR.

To whom correspondence should be addressed.

(^1)
The abbreviation used is: TAF, TATA-binding protein-associated factors.

(^2)
Y.-Z. Liu, S. J. Dawson, and D. S. Latchman, submitted for publication.


ACKNOWLEDGEMENTS

We thank Ron Liem for the -77 alpha-internexin construct and Tarik Möröy for the Brn-3 constructs.


REFERENCES

  1. Bauknecht, T., Jundt, F., Herr, I., Oehler, T., Delius, T., Shi, Y., Angel, P., and Zur Hausen, H. (1995) J. Virol. 69, 1-12 [Abstract]
  2. Bradford, M. M. (1976) Anal. Biochem 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  3. Budhram-Mahadeo, V., Theil, T., Morris, P. J., Lillycrop, K. A., Möröy, T., and Latchman, D. S. (1994) Nucleic Acids Res. 22, 3092-3098 [Abstract]
  4. Budhram-Mahadeo, V., Lillycrop, K. A., and Latchman, D. S. (1995a) Neurosci. Lett. 185, 48-51 [CrossRef][Medline] [Order article via Infotrieve]
  5. Budhram-Mahadeo, V., Morris, P. J., Lakin, N. D., Theil, T., Ching, G. Y., Lillycrop, K. A., Möröy, T., Liem, R. K. H., and Latchman, D. S. (1995b) J. Biol. Chem. 270, 2853-2858 [Abstract/Free Full Text]
  6. Chen, J. L., Attardi, L. D., Verrijzer, C. P., Yokomori, K., and Tjian, R. (1994) Cell 79, 935-105 [Medline] [Order article via Infotrieve]
  7. Ching, G. Y., and Liem, R. K. H. (1991) J. Biol. Chem. 266, 19459-19468 [Abstract/Free Full Text]
  8. Desai, C., Garriga, G., McIntire, S. L., and Horvitz, H. R. (1988) Nature 336, 638-646 [CrossRef][Medline] [Order article via Infotrieve]
  9. Falkner, F. G., Moickat, R., and Zachau, H. G. (1986) Nucleic Acids Res. 13, 7847-7863 [Abstract]
  10. Finney, M., Ruvkun, G., and Horvitz, H. R. (1988) Cell 55, 757-769 [Medline] [Order article via Infotrieve]
  11. Gerrero, M. R., McEvilly, R. J., Tuner, E., Lin, C. R., O'Connell, S., Jenne, K. J., Hobbs, M. V., and Rosenfeld, M. G. (1993) Natl. Acad. Sci. U. S. A. 90, 10841-10845 [Abstract]
  12. Gorman, C. M. (1985) in DNA Cloning: A Pratical Approach (Glover, D. M., ed) pp. 143-190, IRL Press, Oxford
  13. Grossmann, M. E., and Tindall, D. J. (1995) J. Biol. Chem. 270, 10968-10975 [Abstract/Free Full Text]
  14. Haas, S., Steplewksi, A., Siracusa, L. D., Amini, S., and Khalili, K. (1995) J. Biol. Chem. 270, 12503-12510 [Abstract/Free Full Text]
  15. He, X., Treacy, M. N., Simmons, D. M., Ingraham, H. A., Swanson, L. S., and Rosenfeld, M. G. (1989) Nature 340, 35-42 [CrossRef][Medline] [Order article via Infotrieve]
  16. Lehming, N., Thanos., D. Brickman, J. M., Ma, J., Maniatas, T., and Ptashne, M. (1994) Nature 371, 175-179 [CrossRef][Medline] [Order article via Infotrieve]
  17. Li, P., He, X., Gerrero, M. R., Mok, M., Aggarwal, A., and Rosenfeld, M. G. (1994) Genes & Dev. 7, 2483-2496
  18. Lillycrop, K. A., Budhram, V. S., Lakin, N. D., Terrenghi, G., Wood, J. N., Polak, J. M., and Latchman, D. S. (1992) Nucleic Acids Res. 20, 5093-5096 [Abstract]
  19. Lillycrop, K. A., Liu, Y. Z., Theil, T., Moroy, T., and Latchman, D. S. (1995) Biochem. J. 307, 581-584 [Medline] [Order article via Infotrieve]
  20. Luckow, B., and Schutz, G. (1987) Nucleic Acids Res. 15, 5490 [Medline] [Order article via Infotrieve]
  21. Macpherson, I., and Stoker, M. (1962) Virology 16, 147-151
  22. Morris, P. J., Theil, T., Ring, C. J. A., Lillycrop, K. A., Möröy, T., and Latchman, D. S. (1994) Mol. Cell. Biol. 14, 6907-6914 [Abstract]
  23. Mukherjee, R., and Chambon, P. (1990) Nucleic Acids Res. 18, 5713-5716 [Abstract]
  24. Ninkina, N. N., Stevens, G. E. M., Wood, J. N., and Richardson, W. D. (1993) Nucleic Acids Res. 21, 3175-3182 [Abstract]
  25. Pan, W. T., Liu, Q., and Bancroft, C. (1990) J. Biol. Chem. 265, 7022-7028 [Abstract/Free Full Text]
  26. Sakai, D. D., Helms, S., Carlstedt-Duke, J., Gustafsson, J. A., Rottman, F. M., and Yamamoto, K. R. (1988) Genes & Dev. 2, 1144-1154
  27. Stark, H. C., Weinberger, O., and Weinberger, J. (1991) Proc. Natl. Acad. Sci. U. S. A. 89, 2180-2184 [Abstract]
  28. Tasset, D., Tora, D., Fromenthal, C., Scheer, E., and Chambon, P. (1990) Cell 62, 1177-1187 [Medline] [Order article via Infotrieve]
  29. Theil, T., McLean-Hunter, S., Zornig, M., and Möröy, T. (1993) Nucleic Acids Res. 21, 5921-5929 [Abstract]
  30. Theil, T., Zechner, U., Klett, C., Adolph, S., and Möröy, T. (1994) Cytogenet. Cell Genet. 66, 267-271 [Medline] [Order article via Infotrieve]
  31. Turner, E. E., Jenne, K. J., and Rosenfeld, M. G. (1994) Neuron 12, 205-218 [Medline] [Order article via Infotrieve]
  32. Van Dijk, M. A., and Murre, C. (1994) Cell 78, 617-624 [Medline] [Order article via Infotrieve]
  33. Verrijzer, C. P., and van der Vliet, P. C. (1993) Biochim. Biophys. Acta 1173, 1-21 [Medline] [Order article via Infotrieve]
  34. Verrijzer, C. P., Chen, J. L., Yokomori, K., and Tjian, R. (1995) Cell 81, 1115-1125 [Medline] [Order article via Infotrieve]
  35. Wegner, M., Drolet, D. W., and Rosenfeld, M. G. (1993) Curr. Opin. Dev. Biol. 5, 488-498
  36. Wilkison, W. O., Min, H. Y., Claffey, K. P., Satterberg, B. L., and Spiegelman, B. M. (1990) J. Biol. Chem. 265, 477-482 [Abstract/Free Full Text]
  37. Wood, J. N., Bevan, S. J., Coote, P., Darn, P. M., Hogan, P., Latchman, D. S., Morrison, C., Rougon, G., Theveniau, M., and Wheatley, S. C. (1990) Proc. R. Soc. Lond. Ser. B Biol. Sci. 241, 187-194 [Medline] [Order article via Infotrieve]
  38. Xiang, M., Zhou, L., Peng, Y. W., Ceddy, R. L., Shows, T. B., and Nathans, J. (1993) Neuron 11, 689-701 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.